 |
|
|
|
|
|
|
Important Notice: The ADDF/ISOA and Alzheimer Research Forum do not endorse any company or product, and listing in this directory is not linked to corporate sponsorship. We do not make a claim to being comprehensive or up to date. If you would like to recommend a company to be listed in the database, please contact us.
|
|
|
 |
|
|
|
|
|
|
Acumen Pharmaceuticals, Inc.
Website: http://www.acumenpharm.com/
Company/Resource Category: In vitro, Cell-based, Proteins/Enzymes, Receptors, Discovery, Development, Clinical, Screening, Chemistry, Biology, Computer-aided Drug Discovery, Data Analysis, Small Molecules, In silico, Pharmacology, Toxicology/ADME, Diagnostic, Structure-based Drug Design, Pharmaceutical
Profile:
Acumen's patent estate covers ADDL-based antibody, vaccine and small molecule therapeutic and preventative approaches to AD and mild cognitive impairment (MCI). Acumen founding scientists have established that ADDLs are highly neurotoxic, their pathology matches AD, and they block essential information storage pathways in nerve cells. ADDLs are elevated more than 70-fold in brains of AD victims. These
discoveries are based on over 6 years of solid science that establish ADDLs as the cause of Alzheimer's. ADDLs are also linked to MCI, a disease that affects more people than Alzheimer's. Acumen scientists invented the first ADDL-based vaccine, demonstrating its capability to stimulate robust ADDL-blocking antibody production. Acumen also has established a therapeutic anti-ADDL antibody program. These antibodies are ADDL-specific - they do not target fibrils (i.e. avoids potential inflammatory response) and do not target monomers (too abundant/expensive to chase and not the cause of AD.) Acumen is currently screening for small molecules that act as ADDL assembly blockers and ADDL signal and receptor antagonists.
|
|
|
|
|
Home
